Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months

Autor:	Magnus Åstrand, Miguel R. Abboud, Videlis Nduba, Jessie Githanga, Adlette Inati, Baba Psalm Duniva Inusa, Philip Maes, Bernhards Ogutu, Kevin Persson, Elena Cela, Glenn Carlson, Maurizio Miano, Anders Berggren, Mohammad Niazi
Rok vydání:	2021
Předmět:	Male Ticagrelor medicine.medical_specialty Platelet Aggregation Cell Anemia Sickle Cell Disease Gastroenterology 03 medical and health sciences 0302 clinical medicine Pharmacokinetics Internal medicine Humans Medicine Platelet activation Palatability Active metabolite business.industry Infant Newborn Infant Hematology medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health Female Human medicine business Platelet Aggregation Inhibitors 030215 immunology Dose selection medicine.drug
Zdroj:	Pediatric Blood and Cancer
ISSN:	1545-5017 1545-5009 0349-2931
DOI:	10.1002/pbc.28977
Popis:	Inhibition of platelet activation may reduce vaso-occlusion rates in patients with sickle cell disease (SCD). In the HESTIA4 (NCT03492931) study, 21 children with SCD received a single oral dose of the antiplatelet agent ticagrelor (0.1 mg/kg = 6 to = 6 to = 12 to
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a2ff3a25611280a53dc82f43eb6dfc https://doi.org/10.1002/pbc.28977 Zobrazit plný text záznamu Plný text